Midea Group Co., Ltd (00300) plans to repurchase 6.5 to 13 billion yuan worth of A-shares.
Midea Group (00300) announced that the company held its fifth board of directors' thirteenth meeting on March 30, 2026. The meeting approved the "Proposal on Repurchasing Company A Shares through Centralized Competitive Bidding" and agreed for the company to repurchase some of the A shares that have already been issued domestically through centralized competitive bidding, for the purpose of implementing equity incentive plans and/or employee shareholding plans.
Midea Group Co., Ltd. (00300) announced that the company held the thirteenth meeting of the fifth board of directors on March 30, 2026, and approved the "Proposal on Repurchasing A-shares of the Company through Centralized Bidding". The company agreed to repurchase some domestically issued A-shares through centralized bidding trading method, to be used for implementing equity incentive plans and/or employee share ownership plans.
Based on the company's current financial situation and operating conditions, the total amount of funds for this repurchase of shares shall not exceed 13 billion yuan and not be less than 6.5 billion yuan. The source of funds will be the company's own funds and/or a special stock repurchase loan provided by the Bank of China Shunde Branch, with the repurchase price not exceeding 100 yuan per share.
Related Articles

Eastroc Beverage (09980) revenue surpassed 20 billion in 2025, with net profit attributable to the mother increasing by 32.72% year-on-year to 4.415 billion.

CHINA LESSO (02128) announces annual performance, with a net profit attributable to shareholders of 1.262 billion yuan, a decrease of 25.08% year-on-year.

NT PHARMA (01011) expects a net loss of approximately RMB 10.9 million to 15.9 million in the fiscal year 2025.
Eastroc Beverage (09980) revenue surpassed 20 billion in 2025, with net profit attributable to the mother increasing by 32.72% year-on-year to 4.415 billion.

CHINA LESSO (02128) announces annual performance, with a net profit attributable to shareholders of 1.262 billion yuan, a decrease of 25.08% year-on-year.

NT PHARMA (01011) expects a net loss of approximately RMB 10.9 million to 15.9 million in the fiscal year 2025.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


